Atulya. M., Angel Alex, Jesil Mathew. A
Email ID Not Available
Atulya. M.1, Angel Alex2, Jesil Mathew. A2*
1CCS National Institute of Animal Health, Baghpat, Uttar Pradesh, India 250609.
2Department of Pharmaceutical Biotechnology, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Udupi, Karnataka. India 576104.
Volume - 14,
Issue - 8,
Year - 2021
The drug discovery and pharmacokinetic studies of drugs of the central nervous system depend on the successful collection of cerebrospinal fluid from lab animal models. Many a time, the treatment regime and management of diseases depends on the penetration and distribution of medicaments across the blood-brain barrier and for which a non-contaminated cerebrospinal fluid sample is essential. The present study was to simplify the cerebrospinal fluid collection from cisterna magna of rat, maximizing the quantity and minimizing the contamination. The rat is anaesthetized with Xylazine Ketamine combination intravenously and was kept on an inverted polypropylene tray with its head down at 45° angle. A depressible surface which look like a rhomb between occipital protuberances and the spine of the atlas becomes noticeable. A butterfly needle attached to a syringe was introduced into the cisterna magna, and cerebrospinal fluid is aspirated. The method is non-invasive and doesn’t require any sophisticated equipment and lessens the chance of contamination of the sample with blood. The technique is also less time consuming and easy to perform.
Cite this article:
Atulya. M., Angel Alex, Jesil Mathew. A. A Non-invasive Method of Cerebrospinal fluid collection from rats for assessing the Cerebrospinal fluid drug content. Research Journal of Pharmacy and Technology. 2021; 14(8):4085-6. doi: 10.52711/0974-360X.2021.00707
Atulya. M., Angel Alex, Jesil Mathew. A. A Non-invasive Method of Cerebrospinal fluid collection from rats for assessing the Cerebrospinal fluid drug content. Research Journal of Pharmacy and Technology. 2021; 14(8):4085-6. doi: 10.52711/0974-360X.2021.00707 Available on: https://rjptonline.org/AbstractView.aspx?PID=2021-14-8-13
1. Hornig CR, Busse O, Dorndorf W, Kaps M. Changes in CSF blood-brain barrier parameters in ischaemic cerebral infarction. J Neurol. 1983; 229(1): 11–6.
2. Pohl D, Rostasy K, Reiber H, Hanefeld F. CSF characteristics in early-onset multiple sclerosis. Neurology. 2004; 63(10): 1966–7.
3. Jung H, Hurtado M, Sanchez M, Medina MT, Sotelo J. Plasma and CSF levels of albendazole and praziquantel in patients with neurocysticercosis. Clin Neuropharmacol. 1990; 13(6): 559–64.
4. Weller M, Stevens A, Sommer N, Schabet M, Wiethölter H. Humoral CSF parameters in the differential diagnosis of hematologic CNS neoplasia. Acta Neurol Scand. 1992; 86(2): 129–33.
5. McDonald WI, Compston A, Edan G, Goodkin D, Hartung H-P, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001; 50(1): 121–7.